Webinar
Whole health evaluation of multi-system risk
GLP-1 insights
How should therapeutic value be evaluated when health outcomes are shaped by interconnected clinical, behavioral, and social factors? Traditional approaches focus on isolated endpoints measured under controlled conditions, often missing how medical, personal, and systemic factors impact broader patient health trajectories.
A whole health evaluation framework addresses this gap by incorporating multi-system risk, comorbidity burden, behavioral factors, care delivery patterns, and social context.
In this webinar, we introduce this framework using GLP-1 receptor agonists (GLP-1 RAs) as a case study to demonstrate how therapies can act as upstream modifiers of multi-system risk across cardiometabolic, renal, and behavioral health domains—and how their real-world impact is shaped by treatment dynamics and patient context.
Drawing on recent analyses, we examine how adherence, discontinuation, and access influence outcomes, and how variation across populations can be explored using real-world patient data. This approach highlights the gap between clinical trial efficacy and real-world effectiveness in diverse populations, supporting more comprehensive, equity-informed evaluation.
What you'll learn:
- Whole health framework: How to evaluate therapeutic impact across clinical, behavioral, and social domains.
- Multi-system risk: How therapies can influence interconnected disease pathways beyond single endpoints.
- Efficacy vs. effectiveness: How real-world treatment dynamics shape realized outcomes.
- Equity and access: How patient context and care delivery patterns influence treatment experience.
